The scourge of diabetes takes a costly toll. According to the CDC’s 2022 National Diabetes Statistics Report, more than 130 million adults in the U.S. have diabetes or prediabetes. That astounding figure adds weight to the impact of recent study results from LifeScan. A research team including LifeScan employees recently published a study report in Diabetes Technology and Therapeutics. The title of the study tells the story: “Real-World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth-Connected Blood Glucose Meter with a Mobile Diabetes Management App.”

The LifeScan study is a retrospective analysis of data from more than 17,000 people with diabetes. Notably, the study participants include both with type 1 diabetes (T1D, 4,154 people) and with type 2 diabetes (T2D, 13,623 people). All study participants used LifeScan’s OneTouch Reveal app with the LifeScan OneTouch Verio Reflect smart blood glucose meter. We covered LifeScan’s OneTouch Verio Reflect smart blood glucose meter and OneTouch Reveal app previously. The study team’s purpose was to determine whether using the smart glucose meter and the app could help people with diabetes improve their glycemic control. In order measure glycemic control during a 90-day study period, the team analyzed blood glucose level data from each of the subjects for the first 14 days and last 14 days of the test period. Among the study findings, all of which showed positive results, people with T1D showed 8.1% improved glucose readings and people with T2D had 11.2% improvement. Study participants with T1D who spent 11 to 20 minutes each week in the OneTouch Reveal app averaged 9.12% reduced hyperglycemic readings and people with T2D reduced hyperglycemic readings by 11.76%.

This study with in-house researchers doesn’t have a control groups to compare T1D and T2D glycemic control levels of people with other interventions or no intervention at all. However, the reported glycemic control improvements are impressive and point the way to further progress in reducing the health burdens and improving outcomes for people with both forms of diabetes.